Repurposing of H1-receptor antagonists (levo)cetirizine, (des)loratadine, and fexofenadine as a case study for systematic analysis of trials on clinicaltrials.gov using semi-automated processes with custom-coded software

    Tim Specht, Roland Seifert
    TLDR Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
    The document discusses the repurposing of H1-receptor antagonists, specifically cetirizine, loratadine, and fexofenadine, using custom-coded software to analyze data from clinicaltrials.gov. The software analyzed metadata from 70 to 104 studies per drug, identifying potential new uses for these drugs in conditions such as asthma, infusion-associated reactions, G-CSF-associated bone pain, alopecia, and COVID-19. For alopecia, topical cetirizine was found to be less effective than minoxidil in improving hair density, but it might have a longer-lasting effect. The document also mentions a study involving 61,627 women that found loratadine and desloratadine improved survival rates in breast cancer and melanoma patients. However, the authors highlight limitations, including reliance on information provided by study authors on clinicaltrials.gov and the challenge of trials not having published results.
    View this study on link.springer.com →

    Cited in this study